Contrave (naltrexone-bupropion) is an FDA-approved weight-loss medication that works on the brain's appetite and reward circuitry instead of the GLP-1 receptor, and in 2026 it still gets prescribed with far less lab oversight than it deserves. This guide covers who Contrave for weight loss actually fits, what a properly supervised prescription looks like, and where it stacks up against GLP-1 alternatives.
TL;DR
- Contrave for weight loss produced roughly 6% average weight loss in the COR-I trial over 56 weeks, not GLP-1-level results.
- Skip any prescriber who doesn't check blood pressure, seizure history, and eating disorder history before the first dose.
- GLP-1 medications like Wegovy and Zepbound outperform Contrave on trial-reported weight loss magnitude for most candidates.
- A full-workup path with quarterly labs beats a mail-order Contrave subscription with zero baseline screening.
Why this matters
Contrave pairs naltrexone, a drug originally approved for opioid and alcohol dependence, with bupropion, an antidepressant and smoking-cessation aid. Combined at specific doses, the two blunt food cravings and reward-driven eating. That combination carries a boxed warning for suicidal thoughts and behavior, contraindications for seizure disorders and eating disorders, and a documented risk of raising blood pressure during titration.
None of that makes Contrave a bad option. It makes Contrave a medication that needs the same rigor any prescription drug with cardiovascular and neurological risk factors needs: a baseline workup, a titration plan, and someone checking back in. A lot of telehealth Contrave for weight loss subscriptions skip all three and just ship the pills.
Who this is for
Contrave for weight loss fits adults with a BMI of 30 or higher, or 27+ with a weight-related condition like hypertension or prediabetes, who have tried structured diet and exercise without durable results. It's a reasonable fit for people who can't tolerate the GI side effects common with GLP-1 injections, who prefer an oral tablet to a weekly injection, or whose eating pattern is driven more by craving and reward than by hunger signaling. It is not a fit for anyone with a seizure history, an active eating disorder diagnosis, uncontrolled hypertension, or current opioid use, since naltrexone blocks opioid receptors outright.
What to look for in Contrave for weight loss under medical supervision
Baseline blood pressure and cardiovascular screening
Bupropion can raise blood pressure, particularly during the first weeks of titration. A clinician should take a baseline reading and recheck it at each dose increase, not just at the first visit. Skipping this step is the single most common shortcut in low-cost telehealth Contrave programs.
Seizure and eating disorder history review
Bupropion lowers the seizure threshold, and Contrave carries a boxed contraindication for anyone with a seizure disorder or a current or past diagnosis of anorexia or bulimia. A real intake asks about this directly rather than relying on a checkbox on a web form.
Structured dose titration
Contrave starts at one tablet daily and escalates over roughly four weeks to two tablets twice daily. Jumping straight to full dose to save an appointment increases nausea, headache, and blood pressure spikes. Choosing a medical weight-loss program that builds in titration check-ins matters more here than with most medications.
Ongoing monitoring, not a one-time script
A single prescription with no follow-up is the wrong model for a drug with a boxed warning and a cardiovascular side-effect profile. Look for a program that rechecks blood pressure and reviews side effects at least once during titration and again at three months.
Willingness to compare against GLP-1 options
A clinician who only sells Contrave has an incentive to recommend Contrave regardless of your labs. A clinician working from a full metabolic panel, including HbA1c and fasting insulin, can tell you honestly whether a GLP-1 medication would likely outperform it for your specific case.
Pathways to get Contrave for weight loss under real supervision
The full-workup path. A membership-based direct primary care model runs baseline labs and blood pressure checks before any prescription and rechecks on a set schedule. GoodLife Health's direct primary care for weight loss management approach, for example, runs a comprehensive Biomarker Audit every 90 days as a matter of protocol, covering lipids, HbA1c, insulin markers, and inflammation, so a clinician can see the full metabolic picture, not just a symptom checklist. Buy — this is the standard any weight-loss medication should be prescribed under, Contrave included.
The in-network primary care path. Your existing PCP can prescribe Contrave and bill it through insurance, but annual physicals mean labs and blood pressure checks might only happen once a year rather than during titration. Consider — workable if you already have the relationship and don't mind slower follow-up.
The mail-order telehealth subscription path. A growing number of platforms sell Contrave for weight loss as a flat-fee monthly subscription with a five-minute intake questionnaire and no blood pressure cuff in sight. Skip — no baseline screening before a drug with a seizure and blood pressure warning is a real safety gap, not a convenience trade-off.
The compounded copycat path. Compounded naltrexone-bupropion blends marketed as cheaper alternatives to brand-name Contrave aren't FDA-approved as a combination product and don't carry the same batch testing. Skip — the savings don't offset the lack of manufacturer oversight on a drug with this side-effect profile.
The GLP-1 comparison path. If labs show elevated HbA1c, fasting insulin resistance, or significant insulin dysregulation, a GLP-1 medication often produces more weight loss than Contrave, per trial data: roughly 15% average with semaglutide in STEP-1, up to about 22.5% with tirzepatide in SURMOUNT-1, individual results vary. Reviewing the best GLP-1 medications for weight loss in 2026 before committing to Contrave is worth the extra week. Consider — especially if your labs point toward metabolic dysfunction rather than craving-driven eating alone.
What to avoid
- A prescriber who skips the interaction check. Naltrexone blocks opioid painkillers outright, and bupropion interacts with MAOIs and other bupropion-containing products (including some smoking-cessation aids). A five-minute online form won't catch this reliably.
- Stopping cold at full dose. Abruptly discontinuing Contrave at the higher dose level can carry withdrawal-adjacent symptoms tied to the bupropion component; a taper plan matters as much as the titration up.
- Expecting GLP-1-level numbers. Contrave's trial data sits around 6% average weight loss over roughly a year. Going in expecting the 15-22% range seen with GLP-1 therapy sets up disappointment and early discontinuation.
Verdict comparison
| Pathway | Baseline screening | Monitoring cadence | Verdict |
|---|---|---|---|
| Full-workup DPC membership | Full biomarker panel + BP | Quarterly, per protocol | Buy |
| In-network primary care | BP check, basic labs | Annual, sometimes sooner | Consider |
| Mail-order telehealth subscription | Often none | Rarely proactive | Skip |
| Compounded naltrexone-bupropion | Varies, unregulated | Inconsistent | Skip |
| GLP-1 medication (as comparison) | Full biomarker panel | Quarterly, per protocol | Consider first |
GoodLife Health's own Cardiometabolic Optimization Membership is built around branded, FDA-approved GLP-1 medications (Wegovy, Zepbound, Ozempic, Mounjaro, and oral Foundayo) and bioidentical hormone optimization, guided by a comprehensive Biomarker Audit every 90 days. Clinical care is delivered by board-certified physicians of Beluga Health, P.A., working under GoodLife Health's clinical protocols. The point isn't that GoodLife Health writes every prescription in this article, it's that the standard of lab-driven, quarterly-monitored care should apply no matter which medication ends up in your treatment plan, Contrave included.
FAQ
What is Contrave and how does it work for weight loss?
Contrave combines naltrexone and bupropion to reduce food cravings and reward-driven eating rather than acting on the GLP-1 receptor. It's FDA-approved for chronic weight management in adults with a BMI of 30+ or 27+ with a weight-related condition.
Is Contrave as effective as Ozempic or Wegovy?
No. Contrave produced roughly 6% average weight loss in the COR-I trial over 56 weeks, compared to about 15% with semaglutide in STEP-1 and up to 22.5% with tirzepatide in SURMOUNT-1. Individual results vary by trial and patient.
What are the side effects of Contrave?
Common side effects include nausea, constipation, headache, dizziness, and insomnia, especially during the four-week titration period. Contrave also carries a boxed warning for suicidal thoughts and behavior tied to the bupropion component.
Who should not take Contrave?
Contrave is contraindicated for people with a seizure disorder, a current or past eating disorder diagnosis such as bulimia, uncontrolled hypertension, or current opioid use. Naltrexone blocks opioid receptors, which can trigger acute withdrawal in opioid users.
How long does it take Contrave to work for weight loss?
Most Contrave regimens use a four-week dose titration before reaching the full dose, and clinical trials measured meaningful weight loss over 56 weeks. Noticeable appetite changes for some patients show up within the first month.
Does insurance cover Contrave for weight loss?
Coverage varies by plan; many insurers still classify weight-loss medications, including Contrave, as excluded benefits. Cash-pay pricing for brand-name Contrave commonly runs in the low hundreds of dollars monthly without a manufacturer savings card.
Can you take Contrave with a GLP-1 medication?
Combining Contrave with a GLP-1 medication isn't standard practice and hasn't been studied in the same trials used to approve either drug individually. Any combination should only happen under direct physician supervision with lab monitoring.
How much weight can you expect to lose on Contrave?
Trial data from the COR-I study showed an average of roughly 6% weight loss over 56 weeks in the full-dose group, with individual results varying based on adherence and baseline metabolic health.
One last thing
Naltrexone and bupropion were both approved for entirely different conditions decades before anyone combined them into Contrave, and that history is exactly why the screening requirements are so specific: a seizure risk from bupropion, an opioid-blocking effect from naltrexone, and a boxed psychiatric warning that has nothing to do with appetite at all. Anyone treating Contrave for weight loss as a simple diet pill is skipping the part of the label that actually matters in 2026.
Related guides
- Health membership plan for weight loss and hormone care
- What to expect at your first telehealth weight-loss consultation
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/